Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice

Circulation Research

Volumn 88, Issue 8, 2001, Pages 780-786

  Van Vlijmen, Bart J M ^a,b   Gerritsen, Gery ^a,b   Franken, Arthur L ^a,b   Boesten, Lianne S M ^a,b   Kockx, Mark M ^c   Gijbels, Marion J ^d   Vierboom, Michel P ^d   Van Eck, Miranda ^a   Van de Water, Bob ^a   Van Berkel, Theo J C ^a   Havekes, Louis M ^b,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Atherosclerosis; Macrophages; p53; Transgenic

Indexed keywords

APOLIPOPROTEIN E3; BROXURIDINE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; HISTOPATHOLOGY; IRRADIATION; MACROPHAGE; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

EID: 0035957575     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/hh0801.089261     Document Type: Article

References (35)

1. Fuster V, Badimion J, Chesebro JH, Fallen JT. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis. 1996;26: 269-284.
2. Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Histology. Chance F, trans. New York, NY: Dover; 1971:1-554.
3. Ross R. The palhogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-909.
4. Kockx MM, Apoptosis in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 1998;18:1519-1522.
5. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma: colocalizalion with interleukin-Iβ-converting enzyme. Am J Pathol. 1995; 147:251-266.
6. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995;91:2703-2711.
7. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol. 1996;149:367-380.
8. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
9. Ihling C. Haendeler J, Menzel G, Hess RD, Fraedrich G. Schaefer HE, Zeiher AM. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J. Pathol. 1998; 185:303-312.
10. Ihling C, Menzel G. Wellens E. Morning JS, Schaefer HE, Zeiher AM. Topographical association between die cyclin-dependent kinases inhibitor P21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. Arteriosclerr Thromb Vase Biol. 1997;17:2218-2224.
11. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999;5: 335-339.
12. Bennett MR, Evan GI, Schwanz SM. Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways. Cric Res. 1995;77:266-273.
13. Bennett MR, Liltlewood TD, Schwart, SM. Weissberg PL. Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediatcd apoptosis. Circ Res. l997;81:591-599.
14. Kinscherf R, Deigner HP, Usinger C. Pill J.,Wagner M, Kamencic H, Hou D, Chen M, Schmiedt W, Schrader M, Kovacs G, Kato K, Metz J. Induction of mitochondrial manganese Superoxide dismutase in macrophages by oxidized LDL: its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits. FASEB J. 1997;11:1317-1328.
15. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, Frants RR, Hofker MH, Havekes LM. Diet-induced hyperli poproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 1994;93:1403-1410.
16. Groot PH, van Vlijmen BJ, Benson GM, Hofker MH, Schiffelers R, Vidgeon-Hart M, Havekes LM. Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thomb Vasc Biol. 1996;16:926-933.
17. Donehower LA, Harvey M. Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.
18. Vierboorn MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med. 1997;186:695-704.
19. van den Maagdenberg AM, Hofker MH, Krimpenfon PJ, de Bruijn I, van Vlijmen B, van der Boom H, Havekes LM, Prants RR, Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem. 1993;268:10540-10545.
20. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990;31:859-869.
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215.
22. Paigen B, Morrow A, Holmes PA, Mitchctl D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68: 231-240.
23. Gijbels MJ, van der Cammen M, van der Laan LJ, Emeis JJ, Havekes LM, Hofker MH, Kraal G. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis. 1999;143:15-25.
24. Kockx MM, Muhring J, Bortier H, De Meyer GR, Jacob W. Biotin- or digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. Am J Pathol. 1996;148:1771-1777.
25. Lutgens E, Daemen M, Kockx M, Doevendans P, Hofker M, Havekes L, Wellens H, de Muinck ED, Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage. Circulation. 1999;99: 276-283.
26. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Cleaves LA, Atkinson .JB, Linton MF. increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A. 1997;94: 4647-4652.
27. Herijgers N, Van Eck M, Groot PH, Hoogerbrugge PM, Van Berkel TJ. Effect of bone marrow transplantation on lipoproten metabolism and atherosclerosis in LDL receptor-knockout mice. Arterioscler Thromb Vase Biol 1997;17:1995-2003.
28. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 1995;96:2170-2179.
29. Hirabayashi Y, Matsuda M, Matumura T. Mitsui H, Sasaki H, Tukada T, Aizawa S, Yoshida K, Inoue T. The p53-deficient hemopoietic stem cells: their resistance to radiation-apoptosis, but lasted transiently. Leukemia. 1997; 11:489-492.
30. Lotem J. Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 1993;82: 1092-1096.
31. Kockx MM, De Meyer GR, Buyssens N, Knaapen MW, Bull H, Herman AG. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Cric Res. 1998;83:378-387.
32. Yao PM, Tabas I. Free cholesterol loading of macrophages induces apoptosis involving the fas pathway. J Biol Chem. 2000;275:23807-23813.
33. Cai W, Devaux B, Schaper W, Schaper J. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 1997;131:177-186.
34. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995;92: 8264-8268.
35. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919-2922.